EICHOR
● Enrolling By Invitation
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
Condition: Cardiovascular Disease With Mention of Arteriosclerosis · Elevated Cholesterol · Familial Hypercholesterolemia · Sponsor: LIB Therapeutics LLC
About this study
The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W \[\<31 days\]) dosing of subcutaneous (SC) LIB003 300 mg administered in patients with CVD or at high risk for CVD (including HoFH and HeFH) on stable diet and oral LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (12)
| NorthShore University Health System | Evanston, Illinois, United States | — |
| Sterling Research Group | Cincinnati, Ohio, United States | — |
| The Lindner Research Center | Cincinnati, Ohio, United States | — |
| Metabolic & Atherosclerosis Research Center (MARC) | Cincinnati, Ohio, United States | — |
| G.B. Pant Institute of Postgraduate Medical Education & Research | New Delhi, India | — |
| Department of Medicine, Hadassah University Hospital | Jerusalem, Israel | — |
| Rabin Medical Center, Beilinson Hospital, | Petah Tikva, Israel | — |
| Lipid Clinic, Oslo University Hospital | Oslo, Norway | — |
| Carbohydrate and Lipid Metabolism Research Unit | Johannesburg, Gauteng, South Africa | — |
| Division of Lipidology, Department of Medicine University of Cape Town | Cape Town, Western Province, South Africa | — |
| Ege University Medical School | Izmir, Bornova, Turkey (Türkiye) | — |
| Afyonkarahisar Health Sciences University | Afyonkarahisar, Turkey (Türkiye) | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04798430